Sector
PharmaceuticalsOpen
₹30.28Prev. Close
₹30.13Turnover(Lac.)
₹0.32Day's High
₹30.65Day's Low
₹29.2252 Week's High
₹44.9652 Week's Low
₹26.1Book Value
₹33.88Face Value
₹10Mkt Cap (₹ Cr.)
30.62P/E
0EPS
0Divi. Yield
018 Sep 2024
12:00 AM
AGM
Announcement Date: 18 Sep, 2024
4 Mar 2025
12:00 AM
Board Meeting
Agenda : Audited Result
18 Sep 2024
12:00 AM
BookCloser
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 10 | 9.88 | 8.74 | 8.74 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 23.82 | 21.82 | 19.62 | 18.02 |
Net Worth | 33.82 | 31.7 | 28.36 | 26.76 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 51.35 | 51.33 | 51.79 | 57.48 |
yoy growth (%) | 0.03 | -0.88 | -9.9 | 13.43 |
Raw materials | -42.17 | -42.57 | -43.29 | -46.1 |
As % of sales | 82.12 | 82.93 | 83.59 | 80.19 |
Employee costs | -3.75 | -3.5 | -1.97 | -2.8 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0.52 | 0.45 | 0.63 | 0.64 |
Depreciation | -1.36 | -1.46 | -2.4 | -2.58 |
Tax paid | -1.01 | -0.12 | -0.31 | -0.48 |
Working capital | 5.74 | 1.76 | 11.4 | -13.41 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0.03 | -0.88 | -9.9 | 13.43 |
Op profit growth | -3.71 | -30.16 | -13.02 | -33.22 |
EBIT growth | -2.55 | -20.71 | -16.11 | -45.68 |
Net profit growth | 899.6 | 1.23 | 103.25 | -90.87 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 |
|---|---|---|---|
Gross Sales | 44.92 | 52.08 | 58.96 |
Excise Duty | 0 | 0 | 0 |
Net Sales | 44.92 | 52.08 | 58.96 |
Other Operating Income | 0.01 | 0.01 | 0.1 |
Other Income | 0 | 0 | 0 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,766.2 | 134.52 | 4,23,770.54 | 1,181.05 | 0.76 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,958.35 | 76.3 | 1,58,175.47 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,486.75 | 25.8 | 1,20,075.94 | 1,438.15 | 0.87 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,183 | 59.05 | 1,07,722.35 | 485 | 0.88 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,434.1 | 51.93 | 1,00,425.74 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
S Nagi Reddy
Independent Director
K Ramchandra Reddy
Whole Time Director & CFO
Koni Reddy
Independent Director
S. Nagavenkata Hareesh
Whole-time Director
S. Manoj Kumar Reddy
Independent Director
Summela Kasu
Company Sec. & Compli. Officer
Namratha Nagla
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Concord Drugs Ltd
Summary
Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved. The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad. State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality.The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing. It is engaged in developing New products Viz MUPS (Multiple Unit Pellet System), Sustained Release, Modified Release pellets with Innovative Drug Delivery Technologies by utilizing best and latest processing machinery. It operates a state of the art, cGMP contract manufacturing Formulation-Fill-Finish facility, providing comprehensive pharmaceutical development and manufacturing services for drug products.
Read More
What is the Concord Drugs Ltd share price today?
The Concord Drugs Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹30.62 today.
What is the Market Cap of Concord Drugs Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Concord Drugs Ltd is ₹30.62 Cr. as of 09 May ‘25
What is the PE and PB ratio of Concord Drugs Ltd?
The PE and PB ratios of Concord Drugs Ltd is 0 and 0.89 as of 09 May ‘25
What is the 52 Week High and Low of Concord Drugs Ltd?
The 52-week high/low is the highest and lowest price at which a Concord Drugs Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Concord Drugs Ltd is ₹26.1 and ₹44.96 as of 09 May ‘25
What is the CAGR of Concord Drugs Ltd?
Concord Drugs Ltd's CAGR for 5 Years at 11.54%, 3 Years at 2.17%, 1 Year at -15.86%, 6 Month at -21.90%, 3 Month at -14.89% and 1 Month at -2.18%.
What is the shareholding pattern of Concord Drugs Ltd?
The shareholding pattern of Concord Drugs Ltd is as follows:
Promoters - 54.39 %
Institutions - 0.00 %
Public - 45.61 %
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
